Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 498

1.

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA.

J Clin Psychiatry. 2007 Jan;68(1):111-9.

PMID:
17284138
2.

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T.

Psychopharmacology (Berl). 2006 Oct;188(3):281-92. Epub 2006 Sep 5.

PMID:
16953381
3.

Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.

Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, McQuade RD.

Curr Med Res Opin. 2006 Nov;22(11):2209-19.

PMID:
17076982
4.

Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.

Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, Oren DA.

J Clin Psychopharmacol. 2007 Apr;27(2):171-6.

PMID:
17414241
5.

Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.

Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, McQuade R, Pikalov AA 3rd, Crandall DT.

J Psychiatr Pract. 2007 May;13(3):170-7.

PMID:
17522560
6.

Intramuscular aripiprazole in the control of agitation.

Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, Pikalov AA 3rd, Crandall DT.

J Psychiatr Pract. 2007 May;13(3):159-69.

PMID:
17522559
7.

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW.

J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530.

8.

Intramuscular aripiprazole in the acute management of psychomotor agitation.

De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, De Persis S, Piazzi G, Simonetti A, Telesforo CL, Sciarretta A, Caccia F, Gentile G, Kotzalidis GD, Girardi P.

Pharmacotherapy. 2013 Jun;33(6):603-14. doi: 10.1002/phar.1260. Epub 2013 Mar 15.

PMID:
23505124
9.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
10.

A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia.

Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA.

J Am Med Dir Assoc. 2009 Jan;10(1):21-7. doi: 10.1016/j.jamda.2008.06.006. Epub 2008 Sep 27.

PMID:
19111849
11.

Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.

Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT.

J Clin Psychiatry. 2007 May;68(5):662-8.

PMID:
17503974
12.

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.

Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.

J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.

PMID:
19230981
13.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.

Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31.

PMID:
17974864
14.

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.

J Clin Psychiatry. 2009 Jan;70(1):25-35. Epub 2008 Dec 2.

PMID:
19192472
15.

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Swainston Harrison T, Perry CM.

Drugs. 2004;64(15):1715-36. Review.

PMID:
15257633
16.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
17.

Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.

Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, Spyker DA, Cassella JV.

J Clin Psychiatry. 2011 Oct;72(10):1313-21. doi: 10.4088/JCP.10m06011yel.

PMID:
21294997
18.

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.

Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 Jan 11;13:20. doi: 10.1186/1471-244X-13-20. Erratum in: BMC Psychiatry. 2014;14:313. BMC Psychiatry. 2014;14:313.

19.

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.

Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG.

J Clin Psychiatry. 2007 Jan;68(1):29-36.

PMID:
17284127
20.

Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline.

Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A 3rd, Pultz JA, Sanchez R, Marcus RN, Crandall DT.

J Clin Psychiatry. 2007 Sep;68(9):1377-83.

PMID:
17915976

Supplemental Content

Support Center